GlassScriptPhysician profile
Carissa A Summa
NPI 1376614669
$2,740.36
in general payments reported to CMS, 2019-2025
19 companies · $771 in 2025
The $771 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $234 · 2023: $640 · 2024: $1,095 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.95 |
| Education | $383.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $533.53 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Organogenesis INC. | $401.34 | 2023-2025 | Cygnus Dual, Puraply Wound Matrix, Simplimax |
| Lilly USA, LLC | $371.60 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $278.88 | 2022-2025 | |
| Abbvie INC. | $185.94 | 2023-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $184.86 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $154.03 | 2023-2025 | Ilumya |
| Genzyme Corporation | $137.19 | 2024-2025 | |
| Galderma Laboratories, L.P. | $85.30 | 2023-2025 | Nemluvio |
| Dermavant Sciences, INC. | $80.80 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $63.39 | 2024-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $56.78 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $44.14 | 2024 | Dupixent |
| Organon LLC | $38.35 | 2025 | Vtama |
| Almirall LLC | $29.64 | 2024 | Seysara |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $28.02 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Incyte Corporation | $25.95 | 2023 | Opzelura |
| Kerecis Limited | $22.16 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merz North America, INC. | $18.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carissa Summa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.